Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants

AIMS: Branebrutinib (BMS‐986195) is a potent, highly selective, oral, small‐molecule, covalent inhibitor of Bruton's tyrosine kinase (BTK). This study evaluated safety, pharmacokinetics and pharmacodynamics of branebrutinib in healthy participants. METHODS: This double‐blind, placebo‐controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Catlett, Ian M., Nowak, Miroslawa, Kundu, Sudeep, Zheng, Naiyu, Liu, Ang, He, Bing, Girgis, Ihab G., Grasela, Dennis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444767/
https://www.ncbi.nlm.nih.gov/pubmed/32198939
http://dx.doi.org/10.1111/bcp.14290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444767/
https://www.ncbi.nlm.nih.gov/pubmed/32198939
http://dx.doi.org/10.1111/bcp.14290

Ejemplares similares